Global Glaucoma Treatment Market size was valued at USD 7.91 Billion in 2020 and is projected to reach USD 13.53 Billion by 2027, growing at a CAGR of 6.98% from 2021 to 2027. Glaucoma is known as the silent thief of sight because most kinds of the disease generate no discomfort or symptoms until significant vision loss occurs. Glaucoma is a collection of eye illnesses that develop when the optic nerve, which transmits information from the eye to the brain, is damaged. The majority of cases are linked to ocular hypertension, a condition in which the pressure inside the eye is higher than normal, although it can also happen when the intraocular pressure is normal. If left untreated, it causes peripheral vision loss, which then progresses to permanent blindness. Glaucoma is the world’s second largest cause of blindness. During normal eye exams, a tonometer is used to measure intraocular pressure (IOP). IOP should be less than 21 mmHg in most cases. Glaucoma treatment options include surgery, laser treatment, and medication, depending on the severity of the condition. The majority of eye drops are used to reduce IOP, which is the initial line of defence against glaucoma. Most people are casual about using eye drops correctly, and failing to take prescribed prescription is a primary cause of blindness. Glaucoma Treatment Market owing to rising prevalence of Glaucoma. For instance, WHO estimates that 4.5 million people are blind due to Glaucoma. In India, Glaucoma is the leading cause of irreversible blindness with at least 12 million people affected and nearly 1.2 million people blind from the disease. Moreover, around 90+ percent of the cases of the glaucoma are undiagnosed in the community. In 2010, around 1.9% of the people in United States age 40 and older. Additionally, technological advancements in the field of ophthalmology and increasing initiatives regarding the awareness of Glaucoma to make aware of the deadly disease. For instance, in March 2020, theme named “sneak thief of sight” has been hosted at Gandhi Thidal as part of a campaign to raise glaucoma awareness. In India, only 5-10% of the people are aware of the disease. However, stringent approval process coupled with the side effects associated with the products are the major factors hampering the growth of the market.